Informazioni sul prodotto
- Ginsenoside Rg5E
- (3β,12β,20E)-12-Hydroxydammara-20(22),24-dien-3-yl 2-O-β-<span class="text-smallcaps">D</smallcap>-glucopyranosyl-β-<smallcap>D</span>-glucopyranoside
- (8xi,9xi,12alpha,13xi,14beta,17beta)-17-[(1E)-1,5-dimethylhexa-1,4-dien-1-yl]-12-hydroxy-4,4,7,10,14-pentamethylgonan-3-yl 2-O-beta-D-glucopyranosyl-beta-D-glucopyranoside
- G-Rg5
- Ginsenoside Rg<sub>5</sub>
- beta-D-Glucopyranoside, (3beta,12beta,20E)-12-hydroxydammara-20(22),24-dien-3-yl 2-O-beta-D-glucopyranosyl-
- β-<span class="text-smallcaps">D</smallcap>-Glucopyranoside, (3β,12β,20E)-12-hydroxydammara-20(22),24-dien-3-yl 2-O-β-<smallcap>D</span>-glucopyranosyl-
- β-D-Glucopyranoside, (3β,12β,20E)-12-hydroxydammara-20(22),24-dien-3-yl 2-O-β-D-glucopyranosyl-
- (3β,12β,20E)-12-Hydroxydammara-20(22),24-dien-3-yl 2-O-β-D-glucopyranosyl-β-D-glucopyranoside
Ginsenoside Rg5 plays a novel role as an IGF-1R agonist, promoting therapeutic angiogenesis and improving hypertension without adverse effects in the vasculature, it can ameliorate lung inflammation possibly by inhibiting the binding of LPS to toll-like receptor (TLR)-4 on macrophages. Ginsenoside Rg5 blocks cell cycle of SK-HEP-1 cells at the Gl/S transition phase by down-regulating cyclin E-dependent kinase activity and that the down-regulation of cyclin E-dependent kinase activity is caused mainly by induced CDK2 inhibitor, p21Cip/WAF1 and decreased levels of cyclin E.
Proprietà chimiche
Richiesta tecnica su: BP-BP1651 Ginsenoside Rg5
Se si desidera richiedere un preventivo o effettuare un ordine, si prega invece di aggiungere i prodotti desiderati al carrello e poi richiedere un preventivo o un ordine dal carrello. È più veloce, più economico, e potrà beneficiare degli sconti disponibili e di altri vantaggi.
